Skip to main content

Publisher: Wiley-Blackwell

Volume 13, Number 7, July 2011

Favourites:
ADD

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
pp. 594-603(10)
Authors: Esposito, K.; Cozzolino, D.; Bellastella, G.; Maiorino, M. I.; Chiodini, P.; Ceriello, A.; Giugliano, D.

Favourites:
ADD

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
pp. 604-614(11)
Authors: Patel, C. G.; Kornhauser, D.; Vachharajani, N.; Komoroski, B.; Brenner, E.; Handschuh del Corral, M.; Li, L.; Boulton, D. W.

Favourites:
ADD

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials
pp. 615-628(14)
Authors: Leiter, L. A.; Betteridge, D. J.; Farnier, M.; Guyton, J. R.; Lin, J.; Shah, A.; Johnson-Levonas, A. O.; Brudi, P.

Favourites:
ADD

JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats
pp. 629-638(10)
Authors: Hata, T.; Mera, Y.; Kawai, T.; Ishii, Y.; Kuroki, Y.; Kakimoto, K.; Ohta, T.; Kakutani, M.

Favourites:
ADD

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes
pp. 639-643(5)
Authors: Torekov, S. S.; Kipnes, M. S.; Harley, R. E.; Holst, J. J.; Ehlers, M. R.

Favourites:
ADD

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
pp. 644-652(9)
Authors: Reasner, C.; Olansky, L.; Seck, T. L.; Williams-Herman, D. E.; Chen, M.; Terranella, L.; Johnson-Levonas, A. O.; Kaufman, K. D.; Goldstein, B. J.

Favourites:
ADD

Rotational co-culture of clonal β-cells with endothelial cells: effect of PPAR-γ agonism in vitro on insulin and VEGF secretion
pp. 662-668(7)
Authors: Paget, M. B.; Murray, H. E.; Bailey, C. J.; Flatt, P. R.; Downing, R.

Favourites:
ADD

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
pp. 669-672(4)
Authors: Sha, S.; Devineni, D.; Ghosh, A.; Polidori, D.; Chien, S.; Wexler, D.; Shalayda, K.; Demarest, K.; Rothenberg, P.

Favourites:
ADD

News and Views
pp. 673-675(3)
Author: Idris, Iskandar

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more